NDA 202133 · Twi Pharms
Fluoxetine Hydrochloride
Fluoxetine Hydrochloride · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Oct 6, 2011
Approved uses
1
Original approval plus efficacy supplements
Registered trials
326
58 Phase 3, 28 recruiting
FAERS reports
13,085
9,897 serious, 1,521 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 6, 2011 Original approval · Type 3 - New Dosage Form LabelReviewSummary Review
1 products under this application
- FLUOXETINE HYDROCHLORIDE · FLUOXETINE HYDROCHLORIDE EQ 60MG BASE · TABLET, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluoxetine" as an intervention, any sponsor and status, largest first.
- Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild SymptomsPivotal-lookingStatus unknown
CardresearchAcademic, hospital or other
NCT04727424 · 7,819 participants (planned) · Start Jan 19, 2021 · Primary completion Jun 1, 2024
Drug: Budesonide Powder; Fluoxetine 20 MG and 1 more · For: Covid19; SARS-Associated Coronavirus
Sites: Belo Horizonte, Brazil; Betim, Brazil; Brumadinho, Brazil · 12 sites in all
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)Pivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT05041907 · 3,800 participants (planned) · Start Sep 30, 2021 · Primary completion Jan 2027
Drug: Nirmatrelvir/ritonavir (e.g. PAXLOVID™); Nitazoxanide and 16 more · For: COVID-19
Sites: Minas Gerais, Brazil; Vientiane, Laos; Kathmandu, Nepal · 7 sites in all
- Study of Neuro-Cognitive Correlates of Pediatric Anxiety DisordersPivotal-lookingRecruiting
National Institute of Mental Health (NIMH)NIH
NCT00018057 · 3,500 participants (planned) · Start Oct 2, 2001 · Primary completion Jan 1, 2029
Drug: Fluoxetine · For: Anxiety Disorders; Major Depressive Disorder
Sites: Bethesda, Maryland; College Park, Maryland
- Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01360866 · 2,944 participants · Start Oct 2011 · Primary completion Apr 18, 2017
Drug: OPC-34712; Escitalopram and 5 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 142 sites in all
- SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research ProjectPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT03466346 · 2,162 participants · Start Aug 31, 2020 · Primary completion May 6, 2024
Drug: Fluoxetine · For: Depression, Unipolar; Posttraumatic Stress Disorder; Trauma
Sites: Kisumu, Kenya · 3 sites in all
- Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentPivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT01838681 · 1,986 participants · Start Jun 2013 · Primary completion Jun 2016
Drug: Placebo; Brexpiprazole and 1 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Cerritos, California; Temecula, California · 107 sites in all
- Efficacy of Fluoxetine - a Trial in StrokePivotal-lookingCompleted
Karolinska InstitutetAcademic, hospital or other
NCT02683213 · 1,500 participants · Start Oct 20, 2014 · Primary completion Jun 2020
Drug: Fluoxetine; Placebo · For: Stroke
Sites: Stockholm, Sweden
- Improving Outcomes in Depression in Primary Care in a Low Resource SettingPivotal-lookingActive, not recruiting
Harvard Medical School (HMS and HSDM)Academic, hospital or other
NCT05944926 · 1,500 participants (planned) · Start Mar 18, 2024 · Primary completion Apr 10, 2026
Drug: Antidepressant medication (fluoxetine) · For: Depression; Depressive Disorder
Sites: Bhopal, India
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache934
- drug ineffective876
- off label use849
- fatigue793
- drug interaction789
- nausea749
- toxicity to various agents730
- intentional overdose684
- dizziness657
- dyspnoea645
- diarrhoea620
- suicide attempt581
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 148 |
| 2005 | 118 |
| 2006 | 100 |
| 2007 | 124 |
| 2008 | 163 |
| 2009 | 107 |
| 2010 | 107 |
| 2011 | 231 |
| 2012 | 224 |
| 2013 | 212 |
| 2014 | 266 |
| 2015 | 383 |
| 2016 | 293 |
| 2017 | 495 |
| 2018 | 584 |
| 2019 | 637 |
| 2020 | 515 |
| 2021 | 714 |
| 2022 | 1,352 |
| 2023 | 1,496 |
| 2024 | 1,738 |
| 2025 | 1,678 |
| 2026 | 1,400 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.
Nuñez NA, Joseph B, Pahwa M, et al. · J Affect Disord 2022 · Network Meta-Analysis, Research Support, N.I.H., Extramural
- Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis.
Zhou X, Teng T, Zhang Y, et al. · Lancet Psychiatry 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.
March JS, Silva S, Petrycki S, et al. · Arch Gen Psychiatry 2007 · Comparative Study, Multicenter Study
- Fluoxetine and congenital malformations: a systematic review and meta-analysis of cohort studies.
Gao SY, Wu QJ, Zhang TN, et al. · Br J Clin Pharmacol 2017 · Meta-Analysis, Systematic Review
- Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis.
Bahji A, Ermacora D, Stephenson C, et al. · J Affect Disord 2020 · Network Meta-Analysis, Systematic Review
- The fetal safety of fluoxetine: a systematic review and meta-analysis.
Riggin L, Frankel Z, Moretti M, et al. · J Obstet Gynaecol Can 2013 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Twi Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.